Quantum Biopharma (NASDAQ:QNTM) Shares Climb 3% – What’s Next?

Quantum Biopharma Ltd. (NASDAQ:QNTM) shares traded up 3% during mid-day trading on Thursday. The stock traded as high as $2.50 and last traded at $2.44. Approximately 52,646 shares were traded during trading, a decline of 63% from the average daily volume of 144,075 shares. The stock had previously closed at $2.37.

Wall Street Analysts Forecast Growth

QNTM has been the topic of a number of recent analyst reports. Rodman & Renshaw began coverage on Quantum Biopharma in a research report on Monday, August 31st. They issued a “buy” rating and a $8.00 price target on the stock. Wall Street Zen upgraded shares of Quantum Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings raised Quantum Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Quantum Biopharma currently has a consensus rating of “Hold” and an average target price of $8.00.

Quantum Biopharma Price Performance

The firm has a 50-day simple moving average of $3.12 and a 200 day simple moving average of $3.90. The stock has a market capitalization of $19.25 million, a P/E ratio of -0.43 and a beta of 0.39.

Quantum Biopharma (NASDAQ:QNTM) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.06).

Hedge Funds Weigh In On Quantum Biopharma

An institutional investor recently bought a new stake in Quantum Biopharma stock. Platform Technology Partners purchased a new position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 41,116 shares of the company’s stock, valued at approximately $199,000. Platform Technology Partners owned 1.08% of Quantum Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum BioPharma Ltd. is a biotechnology company focused on developing treatments for neurodegenerative and neurological disorders. Its lead drug candidate, Lucid-21-302, also known as Lucid-MS, is an orally administered small molecule being developed as a potential therapy for multiple sclerosis. The company is investigating the compound’s ability to protect nerve cells and promote remyelination, or the repair of damaged myelin.

Quantum BioPharma is also pursuing additional applications for its drug-development platform, including potential treatments for other neurodegenerative and mental health conditions.